Clinical study reveals high claudin 18.2 expression lacks correlation with overall survival in gastric adenocarcinoma, indicating it serves as a predictive rather than prognostic marker.
CLDN18.2 expression was quite high in patients with gastric adenocarcinoma, identifying the proportion of the patients in whom zolbetuximab would be efficacious. There is no statistically significant correlation with clinicopathological characteristics and OS. CLDN18.2 is not a prognostic marker in patients with gastric adenocarcinoma, although it is predictive.
No takes yet. Share an insight, caveat, or question.
Kayıkçıoğlu et al. (2023) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: